Home  /  Investors

Investing in XVIVO

Company overview

XVIVO is a world leader in organ transplantation and the only MedTech company dedicated to extending the life of all major organs. Our services and innovative machine perfusion technologies allow transplantation teams to preserve, transport and assess donor organs outside the body, ultimately saving more lives. We are guided by our purpose, “Nobody should die waiting for a new organ,” and strive every day to enable clinicians and researchers to push the boundaries of organ transplantation. As we do so, we are committed to delivering long-term value to healthcare systems and our shareholders.

XVIVO as an investment

High growth potential, contributing to saving more lives in a rapidly changing market

Market potential for machine perfusion is 10x larger than current standard of care

XVIVO’s offer increases the availability of transplantable organs

History of continuous profitable growth and high margins

Future-secured product portfolio and track record of successfully bringing innovation to market

Latest press releases

11 Apr, 2024
Results from XVIVO’s clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague
8 Apr, 2024
Conference call on Interim Report
4 Apr, 2024
Annual Report 2023
21 Mar, 2024
4 Apr, 2024
Annual Report 2023
25 Jan, 2024
XVIVO presents Report on Operations 2023
24 Oct, 2023
Interim report January-September 2023
13 Jul, 2023
XVIVO presents interim report January-June 2023

Financial calendar

Interim Reports and Reports on Operations are always released at 7:30 AM CET, with the Earnings Call scheduled for the same day at 2:00 PM CET.

Investor relations

Kristoffer Nordström

Kristoffer Nordström, CFO & Investor Relations

Fill out the form to watch the video